Oct. 28, 2013
(NYSE: PHG; AEX: PHIA) and
, a medical device company committed to advancing the diagnosis and management of coronary artery disease today announced a non-exclusive resale agreement for Infraredx's
TVC Imaging System
. Under the terms of the agreement, Philips will sell Infraredx's TVC Imaging System alongside its Allura interventional X-ray systems in
, expanding its interventional cardiology portfolio of advanced live image guidance solutions, clinical informatics and interventional tools.
Coronary artery disease (CAD) is caused when plaque builds up along the inner walls of the coronary (heart) arteries, causing them to narrow and reduce blood flow to the heart muscle. It can be treated with percutaneous coronary intervention (PCI), a catheter-based procedure that is performed in a cath lab under interventional X-ray guidance. Increasingly, additional catheter-based intravascular imaging technologies, such as the TVC Imaging System, are being used to assess the structure and composition of plaques from within the blood vessel, and to guide the interventional treatment for better procedural outcomes.
The TVC Imaging System is a first-in-class intravascular imaging system that integrates near-infrared spectroscopy (NIRS) lipid core plaque (LCP) detection technology, and enhanced intravascular ultrasound (IVUS) imaging to visualize the presence of plaques, quantify the degree of vessel stenosis (narrowing) and identify plaques prone to rupturing and causing dangerous blockages.
"Our goal is to further improve existing image-guided interventions and therapies and to enable new ones," said Ronald Tabaksblat, general manager, interventional X-ray at Philips Healthcare. "By teaming up with Infraredx to sell the TVC Imaging System, our product portfolio will be enhanced with an innovative intravascular imaging technology that works seamlessly with our interventional X-ray systems for better-informed treatment decisions and real-time therapy monitoring."